Misbah Tahir - Nov 23, 2022 Form 4 Insider Report for IGM Biosciences, Inc. (IGMS)

Role
Chief Financial Officer
Signature
/s/ Misbah Tahir
Stock symbol
IGMS
Transactions as of
Nov 23, 2022
Transactions value $
-$14,385
Form type
4
Date filed
11/28/2022, 07:31 PM
Previous filing
May 26, 2022
Next filing
Dec 20, 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IGMS Common Stock Award $4.53K +353 +1.05% $12.84 34.1K Nov 15, 2022 Direct F1
transaction IGMS Common Stock Sale -$12.8K -600 -1.76% $21.38 33.5K Nov 23, 2022 Direct F2, F3
transaction IGMS Common Stock Sale -$6.09K -277 -0.83% $21.99 33.2K Nov 23, 2022 Direct F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares were acquired under the IGM Biosciences, Inc. 2019 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
F2 These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units.
F3 This transaction was executed in multiple trades at prices ranging from $20.74 to $21.73. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F4 This transaction was executed in multiple trades at prices ranging from $21.74 to $22.44. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.